Adjusted Free Cash Flow Performance Measure

RNS Number : 7999U

GlaxoSmithKline PLC

31 July 2015

 



GlaxoSmithKline plc

(the 'Company')

Adjusted Free Cash Flow Performance Measure for 2015-17 awards

under GlaxoSmithKline Share Plans

GSK has today set out the Adjusted Free Cash Flow (AFCF) Performance Measures for the conditional award of shares under the Group's Performance Share Plan and Deferred Annual Bonus Plan for the period 2015-2017. Conditional awards are subject to the achievement of three equally weighted performance measures:

1) Total Shareholder Return (TSR)

2) R&D new product performance

3) Adjusted Free Cash Flow (AFCF)

The use of cash flow as a performance measure is intended to recognise the importance of effective working capital management and of generating cash to fund the Group's operations, investments, and ordinary dividends to shareholders.

Details of the TSR and R&D new product performance measures were set out in an announcement on 12 February 2015 and in the company's Annual Report.  At the time of the grant it was determined that, given the transformational nature of the three-part transaction with Novartis, the AFCF measure and associated vesting levels would be established following the completion of the transaction. 

In considering the AFCF performance measures for the period 2015-17, the Remuneration Committee has considered GSK's future business performance and the scale of restructuring triggered by the Novartis transaction across the Group's three businesses.

As a result, the Remuneration Committee has determined a threshold performance level for AFCF of £11.5 billion over the period 2015-17. This level reflects an estimated reduction of £2.2 billion due to currency movements for the period 2015-17 compared to 2014-16. 

In addition, in order to fully assess disciplined use of restructuring funds over the period 2015-2017,  the Remuneration Committee has decided to exclude the costs and associated capital expenditure for the Group's restructuring and integration programmes, triggered by the Novartis transaction, from the AFCF used to set the performance measures. The Committee has set a specific target of £3.3 billion for this restructuring and capital expenditure.

The vesting schedule is as outlined below:

Performance Level	Adjusted Free Cash Flow (£billions)	Proportion  Vesting %
Below threshold	<11.5	0%
Threshold	11.5	25%
	11.9	50%
	13.0	75%
Maximum	13.6	100%

V A Whyte

Company Secretary

31 July 2015

 

END

 

 

MSCPKDDBABKDKON